Protagonist Therapeutics receives orphan drug designation from the EMA for PTG-300 in polycythemia vera


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Protagonist Therapeutics receives orphan drug designation from the EMA for PTG-300 in polycythemia vera
Protagonist Therapeutics has previously received orphan drug designation for the treatment of polycythemia vera from US FDA

Protagonist Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted orphan drug designation for PTG-300 in the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin and has previously received orphan drug designation for the treatment of polycythemia vera from the U.S. Food and Drug Administration (US FDA).

"This designation reflects the potential of PTG-300 as a treatment candidate and the global need for novel treatments for individuals living with polycythemia vera," commented Samuel Saks, M.D., Protagonist Chief Medical Officer. "Early clinical results that were reported in May, as well as the novel non-cytoreductive therapeutic mechanism of PTG-300 in regulating iron, suggest that PTG-300 may help a broad population of polycythemia vera patients."

He has further added, "We are currently engaged in discussions with leaders in treatment of polycythemia vera to design a pivotal study. Completion of enrollment for the ongoing study of 50 patients is expected in mid-2021. A pivotal study is expected to begin in the second half of 2021, pending our planned discussions with regulatory agencies."

Polycythemia vera is a myeloproliferative neoplasm characterized primarily by the increased production of red blood cells. Well-established treatment guidelines focus on maintaining hematocrit levels continuously below 45 per cent to reduce the risk of thrombotic events. Unfortunately, current treatment options are unable to maintain hematocrit to below the 45 per cent target for many patients and may be associated with serious side effects. There are an estimated 100,000 patients with polycythemia vera in the U.S. and approximately 100,000 patients in major EU countries.

Tags : #ProtagonistTherapeutics #LatestNewsonProtagonistTherapeutic22ndOct #LatestUSFDAApprovalNews22ndOct #LatestEMAApprovalNews22ndOct #LatestPharmaNews22ndOct #SamuelSaks

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025
A 69-year-old retired teacher gives a lesson of life by donating multiple organsJuly 05, 2025
Silent Scans, Smarter Eyes: Inside India’s First AI Teleradiology HubsJuly 05, 2025
Can You Hear Me Now? The Quiet Revolution of Tele-Audiology in Rural Childhood CareJuly 05, 2025
What’s on Their Plate? Uncovering Malnutrition Through Midday Meal DataJuly 05, 2025
Can Diabetics Conquer Space? The Mission That’s Changing Medicine on Earth and BeyondJuly 05, 2025
Center for Diagnostics and Telemedicine Celebrates Graduation of First Masters in Medical Artificial IntelligenceJuly 04, 2025
Sightsavers India Fellowship Programme Invites Applications for 2025July 04, 2025
After 4 Surgeries & 15kg Abdominal Tumour, 61-YO Reclaims Life In Marathon Operation At HCGMCCJuly 04, 2025
The DNA Warning: Are Genomic Screening Camps the Early Alarm We Need?July 04, 2025
Ticked, Tapped, and Forgotten? The Truth About Digital Consent FormsJuly 04, 2025
Evaluating the Impact of AI Chatbots in Mental Health Support for College StudentsJuly 04, 2025
Integrating Oral Health with Primary Care: Pilot Programs in Rural MaharashtraJuly 04, 2025
Will governments firewall public health from tobacco industry's lies and deceptive tactics?July 03, 2025